IDEAYA Biosciences (IDYA) Operating Leases (2019 - 2026)
IDEAYA Biosciences (IDYA) posted Operating Leases of $28.2 million for Q1 2026, up 2.45% sequentially from $27.6 million in Q4 2025, and up 10.09% YoY from $25.7 million in Q1 2025.
IDEAYA Biosciences (IDYA) Operating Leases (2019 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Operating Leases for 8 years, with the latest figure at $28.2 million in Q1 2026.
- Quarterly Operating Leases rose 10.09% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 10.09% YoY) and the FY2025 annual result came in at $27.6 million, up 46.11% from the prior year.
- Operating Leases grew to $28.2 million in Q1 2026 per IDYA's latest filing, from $27.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $28.2 million in Q1 2026 and troughed at $611000.0 in Q2 2023.
- A 5-year average of $11.7 million and a median of $2.8 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2025: Operating Leases plunged 76.24% in 2023, then surged 1980.68% in 2025.
- Over 5 years, Operating Leases stood at $1.6 million in 2022, then tumbled by 30.17% to $1.1 million in 2023, then surged by 1577.6% to $18.9 million in 2024, then surged by 46.11% to $27.6 million in 2025, then climbed by 2.45% to $28.2 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $28.2 million, $27.6 million, and $26.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.12 Mn |
| Mar 31, 2026 | 28.25 Mn |
| Dec 31, 2025 | 27.58 Mn |
| Sep 30, 2025 | 26.92 Mn |
| Jun 30, 2025 | 26.28 Mn |
| Mar 31, 2025 | 25.66 Mn |
| Dec 31, 2024 | 18.87 Mn |
| Sep 30, 2024 | 18.80 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Jun 30, 2023 | 611,000.00 |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.57 Mn |
| Mar 31, 2022 | 3.03 Mn |
| Dec 31, 2021 | 3.48 Mn |
| Sep 30, 2021 | 3.92 Mn |
| Jun 30, 2021 | 4.36 Mn |